Sarcomas
Peg-doxorubicin vs ABV in Kaposi sarcoma | 1998 | Sarcoma |
Paclitaxel vs peg-Doxorubicin in in Kaposi sarcoma | 2010 | Sarcoma |
Eribulin vs dacarbazine liposarcoma | 2016 | Sarcoma |
Trabectedin vs Dacarbazine in liposarcoma | 2016 | Sarcoma |
GeDDiS trial, Doxorubicin vs gem/docetaxel in soft-tissue sarcoma | 2017 | Sarcoma |
Peg-doxorubicin vs ABV in Kaposi sarcoma
Northfelt D W et al, 1998, JCO, PMID: 9667262
Sarcoma
Background: Phase III randomized control trial that included 258 patients with advanced AIDS related Kaposi sarcoma with at least 25 mucocutaneous lesions (or ≥10 new in past month) or documented visceral disease, and serologic evidence of human immunodeficiency virus (HIV) infection, a Karnofsky >40%, LVEF wnl, Hb>8, WBC >1,200.hemoglobin level greater than 8 g/dL, neutrophil count greater than 1,200 cells/pL, platelet count greater than 75,000 cells/pL
Arm A: Pegylated-liposomal doxorubicin 20 mg/m2 q2wk x6 cycles
Arm B: Doxorubicin 20 mg/m2, bleomycin 10 mg/m2 and vincristine 1 mg (ABV) q2wk x6 cycles
Primary Endpoint: Response Rate
ORR: 45.9% vs 24.8%, respectively, P < .001
No survival difference, median OS ~5.5m
Adverse events. Severe adverse events were 15.7% vs 14.9%. More common adverse events were Leukopenia (71.9% vs 50.8%), oral Candidiasis (28.9% vs 17.5%), infection (19.8% vs 13.3%), fever (15.7% vs 25%), N/V (15.7% vs 25%). Completed treatment: 68% vs 34%
Conclusions. Pegylated-liposomal doxorubicin is more effective and less toxic than the standard combination chemotherapy regimen ABV for treatment of Advanced AIDS Kaposi Sarcoma
Summarized by Pragnan Kancharla, MD